AVTR (Avantor, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by AVTR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-20 | Emmanuel Ligner | President and CEO | F | — | — |
| 2026-08-18 | Brittany Hankamer | EVP, Chief HR Officer | F | — | — |
| 2026-08-04 | Steven W Eck | SVP & Chief Accounting Officer | F | — | — |
| 2026-07-27 | Claudius Sokenu | EVP, Chief Legal & Compliance | F | — | — |
| 2026-06-22 | Corey Walker | President, VWR Dist. & Servs. | F | — | — |
| 2026-05-11 | GREGORY L SUMME | Director | A | — | — |
| 2026-05-11 | MICHAEL SEVERINO | Director | A | — | — |
| 2026-05-11 | SANJEEV K MEHRA | Director | A | — | — |
| 2026-05-11 | Joseph R Massaro | Director | A | — | — |
| 2026-05-11 | Louise Makin | Director | A | — | — |
| 2026-05-11 | Simon Dingemans | Director | A | — | — |
| 2026-05-11 | GREGORY T LUCIER | Director | MIXED | — | — |
| 2026-05-11 | Mala Murthy | Director | A | — | — |
| 2026-05-05 | Ludovic Brellier | EVP, Bioscience & Medtech | A | — | — |
| 2026-05-05 | Simon Dingemans | Director | Buy | — | — |
| 2026-04-06 | Steven W Eck | SVP & Chief Accounting Officer | A | — | — |
| 2026-03-11 | SANJEEV K MEHRA | Director | Buy | — | — |
| 2026-02-25 | Steven W Eck | SVP & Chief Accounting Officer | F | — | — |
| 2026-02-25 | Benoit Gourdier | EVP, Bioscience & Medtech | F | — | — |
| 2026-02-25 | R. Brent Jones | EVP, Chief Financial Officer | F | — | — |
| 2026-02-25 | Brittany Hankamer | EVP, Chief HR Officer | F | — | — |
| 2026-02-25 | Claudius Sokenu | EVP, Chief Legal & Compliance | F | — | — |
| 2026-02-23 | R. Brent Jones | EVP, Chief Financial Officer | MIXED | — | — |
| 2026-02-23 | Benoit Gourdier | EVP, Bioscience & Medtech | MIXED | — | — |
| 2026-02-23 | Claudius Sokenu | EVP, Chief Legal & Compliance | MIXED | — | — |
| 2026-02-23 | Corey Walker | President, VWR Dist. & Servs. | MIXED | — | — |
| 2026-02-23 | Emmanuel Ligner | President and CEO | A | — | — |
| 2026-02-23 | Steven W Eck | SVP & Chief Accounting Officer | MIXED | — | — |
| 2026-02-23 | Mary Blenn | EVP, Chief Operating Officer | A | — | — |
| 2026-02-23 | GREGORY T LUCIER | Director | Buy | — | — |
| 2026-02-23 | Brittany Hankamer | EVP, Chief HR Officer | MIXED | — | — |
| 2026-02-12 | GREGORY L SUMME | Director | Buy | — | — |
| 2026-01-12 | Simon Dingemans | Director | A | — | — |
| 2025-12-09 | SANJEEV K MEHRA | Director | MIXED | — | — |
| 2025-11-17 | Emmanuel Ligner | President and CEO | Buy | — | — |
| 2025-11-12 | Mary Blenn | EVP, Chief Operating Officer | A | — | — |
| 2025-10-31 | GREGORY L SUMME | Director | Buy | — | — |
| 2025-10-07 | GREGORY T LUCIER | Director | A | — | — |
| 2025-10-03 | Benoit Gourdier | EVP, Bioscience Production | F | — | — |
| 2025-08-22 | GREGORY L SUMME | Director | Buy | — | — |
| 2025-08-21 | Emmanuel Ligner | President and CEO | A | — | — |
| 2025-08-15 | Brittany Hankamer | EVP, Chief HR Officer | F | — | — |
| 2025-08-12 | Christophe Couturier | EVP, AMEA | A | — | — |
| 2025-08-06 | Steven W Eck | SVP & Chief Accounting Officer | Sell | — | — |
| 2025-08-04 | Steven W Eck | SVP & Chief Accounting Officer | F | — | — |
| 2025-07-25 | Claudius Sokenu | EVP, Chief Legal & Compliance | F | — | — |
| 2025-06-24 | Corey Walker | President Laboratory Solutions | F | — | — |
| 2025-05-27 | GREGORY L SUMME | Director | Buy | — | — |
| 2025-05-22 | GREGORY L SUMME | Director | Buy | — | — |
| 2025-05-21 | Michael Stubblefield | President & CEO | G | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 110,477,989 | — |
| — | 10%+ Owner | 89,591,565 | — |
| — | Director | 72,623,882 | — |
| — | 10%+ Owner | 72,620,082 | — |
| — | 10%+ Owner | 72,605,349 | — |
| — | 10%+ Owner | 71,471,429 | — |
| — | 10%+ Owner | 64,016,093 | — |
| — | 10%+ Owner | 58,882,183 | — |
| — | 10%+ Owner | 43,483,708 | — |
| — | 10%+ Owner | 28,000,000 | — |
| — | President & CEO | 1,764,513 | — |
| — | Director | 1,058,671 | — |
| — | President and CEO | 737,334 | — |
| — | Director | 650,317 | — |
| — | Director | 508,376 | — |
| — | Director | 483,381 | — |
| — | EVP, Chief Financial Officer | 419,782 | — |
| — | President, VWR Dist. & Servs. | 384,535 | — |
| — | EVP, Bioscience & Medtech | 362,859 | — |
| — | EVP, Chief Operating Officer | 253,384 | — |
| — | EVP, Chief Legal & Compliance | 251,228 | — |
| — | EVP, Chief HR Officer | 248,864 | — |
| — | EVP, IMEA | 239,095 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AVTR quote page; the site-wide leaderboard is on the insider transactions hub.